Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of clinically localized adenocarcinoma of the prostate
• * T1 or T2 disease
• Received prior primary treatment with definitive radiotherapy (at least 5,500 cGy) OR radical prostatectomy
• Biochemical relapse within 5 years after prior primary therapy, defined as 1 of the following:
• * Detectable and rising prostate-specific antigen (PSA) after surgery (at least 2 values above the residual cancer detection limit of the assay)
• * PSA at least 2 values above 1 ng/mL OR at least 3 rising values at any level after radiotherapy
• PSA no greater than 10 ng/mL
• PATIENT CHARACTERISTICS:
• Age
• Not specified
• Performance status
• ECOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Not specified
• Hepatic
• ALT no greater than 2.5 times upper limit of normal
• Renal
• Creatinine normal
• Other
• No allergy to cyclooxygenase-2 inhibitors, aspirin, nonsteroidal anti-inflammatory drugs, or sulfa drugs
• No untreated peptic ulcer disease
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• No prior chemotherapy
• Endocrine therapy
• More than 6 months since prior adjuvant or neoadjuvant hormonal therapy
• * Duration of prior adjuvant or neoadjuvant hormonal therapy must have been no more than 6 months
• Radiotherapy
• See Disease Characteristics
• Prior salvage radiotherapy after prostatectomy allowed
• Surgery
• See Disease Characteristics